Eli Lilly and Company announces that it will present new data from Taltz (ixekizumab), Olumiant (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting.
The data being highlighted at this year’s virtual conference include the latest therapeutic data available in dermatological conditions such as psoriasis and atopic dermatitis (AD). Lilly will present 24 e-Posters, including 14 for Taltz, five for baricitinib, three for mirikizumab and two for lebrikizumab.
“At Lilly, we discover and develop new medicines because we want to help people get better and feel better,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “We’re pleased to share new data from our dermatology pipeline at the virtual AAD meeting because we believe our medicines have the potential to help people living with dermatological conditions.”
Lilly announced earlier this year that it would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly’s commitment to dermatology and creating new medicines for those living with skin-related diseases. Through the virtual conference, Lilly will be sharing long term data from Taltz clinical trials on itch, skin pain and health related quality of life for patients with moderate to severe plaque psoriasis who have been on the medicine for up to five-years of continuous treatment. Additional new study results will be disclosed exploring, through drug survival, the effectiveness of Taltz in the real-world setting; health economic data associated with Taltz cumulative clinical benefit will also be presented.
Data being presented on baricitinib support the medicine’s potential to be a treatment option for adult patients with moderate to severe AD. Highlights of the data being presented at this year’s AAD meeting include additional results from BREEZE-AD1 and BREEZE-AD2, Lilly’s Phase 3 trials that are part of the baricitinib development program to support global submissions for baricitinib as a treatment for AD.
Lilly will also highlight Phase 2 safety and efficacy data from its investigational medicine mirikizumab in patients with moderate to severe plaque psoriasis. In addition, Lilly will be highlighting data surrounding the investigational therapy lebrikizumab and results from its Phase 2b studies, which is currently being measured in adult patients with moderate to severe AD.
[Source(s): Eli Lilly and Company, PR Newswire]